A new contender in the global weight-loss drug market is emerging from China. Jiangsu-based Hengrui Pharma, together with its U.S. partner Kailera Therapeutics, has announced encouraging late-stage trial results for HRS9531, an investigational obesity treatment showing comparable efficacy to leading therapies on the market. In a 48-week Phase 3 trial, patients on HRS9531 lost an average of 18% of their body weight, with that number rising to 19% among those who completed the trial. While Eli Lilly’s Zepbound (tirzepatide) demonstrated 21% weight loss in a longer trial, the Hengrui study suggests the potential for higher outcomes, especially since the highest ...

As biotechnology rapidly becomes one of the most strategic sectors in global science and innovation, China has emerged not just as a participant but a potential frontrunner. From pioneering gene-editing therapies to challenging the dominance of Western pharma giants, China’s biotech ascent reflects more than just scientific ambition—it signals a recalibration of global technological power. For countries like India, the window to catch up is narrowing. Biotech has long been framed by dual narratives: a promise of transformative healthcare solutions and a cautionary tale of bioethics and geopolitical risk. China, more than any other nation, embodies this paradox. Global scrutiny ...

China’s biotechnology sector is experiencing an explosive resurgence, with its performance this year surpassing even the much-hyped artificial intelligence wave. After years of subdued investor interest, the sector is seeing a dramatic reversal, driven by landmark licensing deals, blockbuster IPOs, and growing global recognition of China’s research capabilities. Since the beginning of 2025, the Hang Seng Biotech Index has soared over 60%, outstripping the 17% rally in China’s tech stocks fueled by DeepSeek’s AI breakthrough. This surge is largely credited to a series of multi-billion-dollar deals that mark a turning point in how Chinese biotech innovation is perceived globally. One ...

China’s biotechnology sector is undergoing a transformative surge—reshaping the global pharmaceutical landscape and solidifying the country’s position as a central force in life sciences innovation. Fueled by a decade-long strategic vision, strong public-private collaboration, and a rapidly maturing R&D ecosystem, China is now at the forefront of drug development, clinical research, and medical innovation. A New Global Leader in Clinical Trials and R&D In 2024, China recorded more than 7,100 clinical trials on the World Health Organization’s International Clinical Trials Registry Platform, marking a new high point in the nation’s scientific output. Cities like Beijing and Shanghai are now global ...

For millions of diabetic patients worldwide, the daily routine of pricking their fingers to measure blood sugar levels is both physically painful and emotionally taxing. However, groundbreaking research unveiled on February 5, 2025, promises to transform diabetes management forever. A collaborative team led by Professor Wang Weiqing from the National Clinical Research Center for Endocrine and Metabolic Diseases at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, alongside the Medical Chip Research Institute of Ruijin Hospital and Researcher Chen Chang’s team from Shanghai Jinguan Technology, has introduced a revolutionary non-invasive blood sugar testing technology. Their findings, published in Nature ...